Beta Drugs Limited (NSE:BETA)
India · Delayed Price · Currency is INR 1,931.25
-27.35 (-1.40%)
At close: Aug 21, 2025
Beta Drugs Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Net Income | 424.19 | 364.37 | 307.19 | 248.28 | 117.25 | Upgrade |
Depreciation & Amortization | 125.14 | 90.85 | 104.1 | 72.54 | 68.74 | Upgrade |
Other Amortization | - | 6.97 | - | - | - | Upgrade |
Other Operating Activities | 2.39 | -17.12 | 19.47 | 73.18 | 38.94 | Upgrade |
Change in Accounts Receivable | -233.38 | -165.17 | -175.41 | -113.05 | -19.5 | Upgrade |
Change in Inventory | -99.6 | -191.94 | -81.37 | -64.39 | -36.96 | Upgrade |
Change in Accounts Payable | 120.04 | 190.33 | 82.88 | 114.58 | 60.05 | Upgrade |
Change in Other Net Operating Assets | 22.96 | 31.01 | -23.04 | -34.86 | -42.52 | Upgrade |
Operating Cash Flow | 361.73 | 309.3 | 233.83 | 296.28 | 186 | Upgrade |
Operating Cash Flow Growth | 16.95% | 32.28% | -21.08% | 59.29% | 121.06% | Upgrade |
Capital Expenditures | -368.59 | -116.16 | -182.12 | -194.28 | -57.56 | Upgrade |
Investment in Securities | - | 7.79 | - | - | -4.27 | Upgrade |
Other Investing Activities | 51.1 | 10.84 | 6.63 | 4.52 | 3.34 | Upgrade |
Investing Cash Flow | -357.18 | -139.72 | -190.69 | -217.55 | -58.48 | Upgrade |
Short-Term Debt Issued | 7.56 | - | 43.14 | 12.14 | - | Upgrade |
Long-Term Debt Issued | 1,237 | - | - | 6.08 | 8.14 | Upgrade |
Total Debt Issued | 1,244 | - | 43.14 | 18.22 | 8.14 | Upgrade |
Short-Term Debt Repaid | - | -41.11 | - | - | -61.08 | Upgrade |
Long-Term Debt Repaid | - | -5.59 | -43.73 | - | - | Upgrade |
Total Debt Repaid | - | -46.7 | -43.73 | - | -61.08 | Upgrade |
Net Debt Issued (Repaid) | 1,244 | -46.7 | -0.59 | 18.22 | -52.94 | Upgrade |
Issuance of Common Stock | 4.81 | - | - | - | - | Upgrade |
Other Financing Activities | -69.89 | -28.2 | -24.15 | -27.95 | -24.2 | Upgrade |
Financing Cash Flow | 1,179 | -74.9 | -24.74 | -9.74 | -77.14 | Upgrade |
Miscellaneous Cash Flow Adjustments | - | - | -0 | - | - | Upgrade |
Net Cash Flow | 1,184 | 94.69 | 18.4 | 68.99 | 50.38 | Upgrade |
Free Cash Flow | -6.86 | 193.15 | 51.71 | 102 | 128.44 | Upgrade |
Free Cash Flow Growth | - | 273.55% | -49.31% | -20.59% | - | Upgrade |
Free Cash Flow Margin | -0.19% | 6.53% | 2.28% | 5.55% | 11.06% | Upgrade |
Free Cash Flow Per Share | -0.68 | 19.13 | 5.12 | 10.11 | 12.72 | Upgrade |
Cash Interest Paid | 69.89 | 26.77 | 22.8 | 17.89 | 22.2 | Upgrade |
Levered Free Cash Flow | -36.77 | 134.52 | -17.57 | 0.72 | 65.3 | Upgrade |
Unlevered Free Cash Flow | 6.91 | 151.25 | -3.32 | 11.9 | 79.18 | Upgrade |
Change in Working Capital | -189.99 | -135.77 | -196.94 | -97.72 | -38.93 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.